DE68926899D1 - Hybride monoklonale Antikörper, ihre Herstellung und Verwendung - Google Patents

Hybride monoklonale Antikörper, ihre Herstellung und Verwendung

Info

Publication number
DE68926899D1
DE68926899D1 DE68926899T DE68926899T DE68926899D1 DE 68926899 D1 DE68926899 D1 DE 68926899D1 DE 68926899 T DE68926899 T DE 68926899T DE 68926899 T DE68926899 T DE 68926899T DE 68926899 D1 DE68926899 D1 DE 68926899D1
Authority
DE
Germany
Prior art keywords
production
monoclonal antibodies
hybrid monoclonal
hybrid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68926899T
Other languages
English (en)
Other versions
DE68926899T2 (de
Inventor
Susumu Iwasa
Tomofumi Kurokawa
Yukio Toyoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE68926899D1 publication Critical patent/DE68926899D1/de
Publication of DE68926899T2 publication Critical patent/DE68926899T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE68926899T 1988-09-27 1989-09-23 Hybride monoklonale Antikörper, ihre Herstellung und Verwendung Expired - Fee Related DE68926899T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤

Publications (2)

Publication Number Publication Date
DE68926899D1 true DE68926899D1 (de) 1996-09-05
DE68926899T2 DE68926899T2 (de) 1997-01-02

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68926899T Expired - Fee Related DE68926899T2 (de) 1988-09-27 1989-09-23 Hybride monoklonale Antikörper, ihre Herstellung und Verwendung

Country Status (15)

Country Link
US (1) US5506135A (de)
EP (1) EP0363712B1 (de)
JP (1) JP3177776B2 (de)
KR (1) KR900004351A (de)
CN (1) CN1041783A (de)
AR (1) AR242832A1 (de)
AT (1) ATE140930T1 (de)
AU (1) AU628857B2 (de)
DE (1) DE68926899T2 (de)
DK (1) DK474189A (de)
FI (1) FI894551A (de)
HU (1) HUT55445A (de)
IL (1) IL91649A (de)
NO (1) NO893818L (de)
PT (1) PT91808B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (de) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
AP257A (en) * 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
SG11201910113PA (en) * 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
ES8504461A1 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
EP0241907A3 (de) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunktionelle Antikörper und Verfahren zur Verwendung derselben

Also Published As

Publication number Publication date
DK474189A (da) 1990-03-28
NO893818L (no) 1990-03-28
IL91649A0 (en) 1990-04-29
KR900004351A (ko) 1990-04-12
US5506135A (en) 1996-04-09
FI894551A0 (fi) 1989-09-26
DE68926899T2 (de) 1997-01-02
NO893818D0 (no) 1989-09-26
PT91808A (pt) 1990-03-30
FI894551A (fi) 1990-03-28
IL91649A (en) 1994-10-21
HUT55445A (en) 1991-05-28
DK474189D0 (da) 1989-09-26
AU4174789A (en) 1990-04-05
ATE140930T1 (de) 1996-08-15
EP0363712A3 (en) 1990-08-16
AR242832A1 (es) 1993-05-31
EP0363712A2 (de) 1990-04-18
AU628857B2 (en) 1992-09-24
JP3177776B2 (ja) 2001-06-18
JPH03103175A (ja) 1991-04-30
PT91808B (pt) 1995-05-31
EP0363712B1 (de) 1996-07-31
CN1041783A (zh) 1990-05-02

Similar Documents

Publication Publication Date Title
DE3588225D1 (de) Anti-Lymphotoxin-Antikörper, Herstellung und Verwendung
DE3581578D1 (de) Antikoerper, herstellung und verwendung.
DE68924026T2 (de) Biosensor und dessen herstellung.
ATE89560T1 (de) Makrolid-derivate, ihre herstellung und ihre verwendung.
DE3884140T2 (de) Azazyklische Verbindungen, ihre Herstellung und ihre Verwendung.
DE3674906D1 (de) Selbstklemmende medizinische prothese und ihre herstellung.
PT85616A (de) Aryloxycarbonsaurederivate ihre herstellung und verwendung
DE3885534D1 (de) Arylphosphorderivate, ihre Herstellung und Verwendung.
DE3777366D1 (de) 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
ATA3589A (de) Neue isochinolinderivate, ihre herstellung und ihre verwendung
DE3785967D1 (de) Monoklonale antikoerper gegen c5a und des-arg74-c5a, ihre herstellung und ihre verwendung.
DE3887820T2 (de) Antibiotika, Benanomicine A und B und Dexylosylbenanomicin B, ihre Herstellung und Verwendung.
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE3784602T2 (de) Inonos-derivate, ihre herstellung und verwendung.
DE3774718D1 (de) Benzothiazolylazolidine und ihre herstellung und verwendung.
DE3682491D1 (de) Immobilisierter c-peptid-antikoerper, seine herstellung und verwendung.
DE58908788D1 (de) Modifizierte Blockpolymerisate, ihre Herstellung und Verwendung.
DE58904018D1 (de) Enantiomere silane, modifiziertes traegermaterial und dessen verwendung.
DE3863191D1 (de) Substituierte aminderivate, ihre herstellung und verwendung.
DE68926899D1 (de) Hybride monoklonale Antikörper, ihre Herstellung und Verwendung
DE3583296D1 (de) Oncofetal spezifische monoklonale antikoerper, deren herstellung und verwendung.
DE68919259T2 (de) N-Phenylimide, ihre Herstellung und Verwendung.
DE58904019D1 (de) Enantiomere silane, modifiziertes traegermaterial und dessen verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee